Cue Biopharma reported topline Phase 2 results for CUE-221 in chronic spontaneous urticaria, showing robust efficacy and a favorable safety profile. The 4 mg/kg dose achieved 54% complete hive resolution at Week 12, with benefits persisting through Week 28 off-drug and a 36% advantage over omalizumab. Management plans a Phase 2b/3 CSU trial alongside a Phase 2 food allergy study, signaling a clear near-term development catalyst.
B. Riley launched coverage on CUE Biopharma with a Buy rating and an $83 target, signaling confidence in the pipeline. The stock closed near $37.84, suggesting substantial upside if milestones validate the thesis. This catalyst-driven coverage may attract more broker reactions and liquidity, potentially lifting shares in the near term.
CUE is progressing in the development of injectable biologics that aim to modulate disease-specific T cells within patients, signaling a potential breakthrough in treatment methodologies. This innovation suggests a growing focus on personalized therapeutics, which could enhance CUE’s market position and appeal to investors.
